Pipeline
Initial R&D portfolio
G Life Quantum is pursuing advanced research activities in multiple fields
* Endovascular systemic blood treatment
* Extravascular systemic blood treatment
* Cardio-protection & regeneration photonic intramyocardial therapy
* Cardio-protection & regeneration photonic endomyocardial therapy
* Stimulator Mitochondrial autologous transplantation
* Stimulator Cell & stem cell therapy
Protection and optimization of mitochondrial respiratory function
Myocardial infarction is one of the most common acute conditions worldwide and a major cause of mortality. Current treatments have only limited effectiveness and can cause cardiomyocyte death up to several days after treatment. By using optimized photonic dosing through QBM, it is possible to ‘precondition’ the heart muscle following hypoxia, to prepare it for reoxygenation.
Anti-inflammatory and immunomodulatory effects
QBM has shown anti-inflammatory and immunomodulatory effects. G Life Quantum develops QBM therapies in the blood that may impact endothelial cell protection and have effects on the cellular metabolism of circulating blood components, which help control the inflammatory and immune response.
Anti-platelet activity
G Life Quantum researchers have finalized the protocol for a phase I clinical study to evaluate the hypothesis that increased circulation of NO should protect against platelet aggregation.
Anti-hypoxemic action
QBM has a specific impact on hemoglobin, oxygen saturation and blood NO concentration. G Life Quantum researchers have measured and quantified these phenomena in real time in the pulmonary and systemic circulations.